AbbVie (NYSE:ABBV) & Verastem (NASDAQ:VSTM) Head-To-Head Review

Verastem (NASDAQ:VSTM) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

88.4% of Verastem shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 1.9% of Verastem shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Verastem and AbbVie”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91 million	33.35	-$209.47 million	($2.05)	-3.99
AbbVie	$66.01 billion	7.90	$4.23 billion	$5.81	50.81

AbbVie has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Verastem has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Verastem and AbbVie, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1	1	11	0	2.77
AbbVie	0	6	22	1	2.83

Verastem currently has a consensus target price of $16.83, suggesting a potential upside of 105.79%. AbbVie has a consensus target price of $297.46, suggesting a potential upside of 0.77%. Given Verastem’s higher probable upside, research analysts clearly believe Verastem is more favorable than AbbVie.

Profitability

This table compares Verastem and AbbVie’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Verastem	-178.38%	-359.49%	-78.60%
AbbVie	15.67%	-450.55%	16.50%

Summary

AbbVie beats Verastem on 9 of the 15 factors compared between the two stocks.

About Verastem

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.

About AbbVie

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.